Merck in Agreement With Cyclica for AI-augmented Screening Platform to Expand Research Capabilities - Seite 2

Traditional development of small molecule therapies focuses on
specific, disease-associated protein targets. However, once a drug
enters the body, it interacts with dozens, if not hundreds, of
proteins before it is eliminated from the body. With Ligand Express®,
it is possible to capture a unique panoramic view of the proteome for
a given small molecule. As the technology can model the ways in which
a small molecule will interact with all proteins (of known
structure), it can help identify both 'on-targets' (interactions that
may have a desirable effect on a certain disease), as well as
'off-targets' (interactions that may cause an adverse effect).

Merck is committed to embracing innovative technologies to help
bring a transformational change to patients. This includes those
developed by partners who share a similar passion for discovery and
advancing human progress.

All Merck Press Releases are distributed by e-mail at the same
time they become available on the Merck Website. Please go to
www.merckgroup.com/subscribe to register online, change your
selection or discontinue this service.

About Merck

Merck, the vibrant science and technology company, operates across
healthcare, life science and performance materials. Around 51,000
employees work to make a positive difference to millions of people's
lives every day by creating more joyful and sustainable ways to live.
From advancing gene editing technologies and discovering unique ways
to treat the most challenging diseases to enabling the intelligence
of devices - Merck is everywhere. In 2017, Merck generated sales of
EUR 15.3 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been
key to Merck's technological and scientific advances. This is how
Merck has thrived since its founding in 1668. The founding family
remains the majority owner of the publicly listed company. Merck
holds the global rights to the Merck name and brand. The only
exceptions are the United States and Canada, where the business
sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma
in life science, and EMD Performance Materials.

About Cyclica

Cyclica is a Toronto-based biotechnology company that is driving
drug discovery by empowering scientists in pharma with an integrated
cloud-based and AI-augmented platform that enhances how they design,
screen and personalize medicines. To learn more, visit
www.cyclicarx.com.

Your Contact

[e-mail]

Phone: [phone]

(Logo: https://mma.prnewswire.com/media/765882/Merck_Logo.jpg )

ots Originaltext: Merck KGaA
Im Internet recherchierbar: http://www.presseportal.de